摘要
目的检测55例晚期肺腺癌初治患者治疗前外周血T淋巴细胞亚群的表达,并探讨其与培美曲塞联合顺铂方案化疗疗效间关系。方法采用流式细胞术检测经病理组织学或细胞学检查确诊的55例晚期肺腺癌初治患者治疗前外周血单个核细胞(PBMC)中总T细胞(CD3+)、Th细胞(CD3+CD4+)、Tc细胞(CD3+CD8+)、CD4+/CD8+、记忆T细胞(CD45RO+)、原始T细胞(CD45RA+)的比例。结果化疗无效组患者外周血原始T细胞高于有效组(P=0.04);化疗有效组患者外周血记忆T细胞较高,但差异尚不具统计学意义(P=0.25);两组总T细胞、Th细胞、Tc细胞及CD4+/CD8+无显著性差异。结论晚期肺腺癌患者外周血原始T细胞与化疗疗效相关,原始T细胞较高者近期疗效差。检测患者外周血原始T细胞对预测患者化疗疗效有一定的预测作用。
Objective To evaluate the clinical value of T lymphocyte subsets in prediction of chemotherapy responses of patients with pulmonary adenocarcinoma.Methods Fifty-five chemotherapy-naive patients with pathologically or cytologically confirmed pulmonary adenocarcinoma were examined for peripheral blood T lymphocyte subsets using flow cytometry,including CD3＋ T cells,CD3＋CD4＋ T cells,CD3＋CD8＋ T cells,CD45RO＋ T cells and CD45RA＋ T cells.Results Patients who responded favorably to chemotherapy（CR＋PR） showed a significantly lower percentage of CD45RA＋ T cells than those who failed to respond to chemotherapy（P=0.04）.CD45RO＋ T cell percentage were slightly higher in the response group than in the non-response group,but this difference was not statistically significant（P=0.25）.The other T cell subsets,namely CD3＋,CD3＋CD4＋,and CD3＋CD8＋ T cells showed no significant differences between the two groups.Conclusion A high percentage of peripheral blood CD45RA＋ T cells is associated with a poor short-term outcome of chemotherapy in patients with advanced pulmonary adenocarcinoma.Peripheral blood CD45RA＋ T cell level can be a reliable index for predicting chemotherapy efficacy in these patients.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2012年第5期752-754,共3页
Journal of Southern Medical University
基金
军队十一五医药卫生科研课题项目(06G106)
关键词
培美曲塞
肺腺癌
化疗
T淋巴细胞亚群
pemetrexed
adenocarcinoma
chemotherapy
T lymphocyte subsets
